NextGen Biomed (XTAE:NXGN) ROE % Adjusted to Book Value : -17.77% (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed ROE % Adjusted to Book Value?

NextGen Biomed's ROE % for the quarter that ended in Jun. 2023 was -36.96%. NextGen Biomed's PB Ratio for the quarter that ended in Jun. 2023 was 2.08. NextGen Biomed's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was -17.77%.

NextGen Biomed ROE % Adjusted to Book Value Historical Data

The historical data trend for NextGen Biomed's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed ROE % Adjusted to Book Value Chart

NextGen Biomed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-11.86

-10.68

-3.15

-6.90

-23.55

NextGen Biomed Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial													-3.65	-3.45	-10.97	-40.00	-17.77

Competitive Comparison of NextGen Biomed's ROE % Adjusted to Book Value

For the Medical Instruments & Supplies subindustry, NextGen Biomed's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextGen Biomed's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NextGen Biomed's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NextGen Biomed's ROE % Adjusted to Book Value falls into.

NextGen Biomed ROE % Adjusted to Book Value Calculation

NextGen Biomed's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-51.82%	/	2.20
	=	-23.55%

NextGen Biomed's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-36.96%	/	2.08
	=	-17.77%

NextGen Biomed ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NextGen Biomed (XTAE:NXGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101

Website

http://www.nextgen-biomed.com

NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.